Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy

British Journal of Cancer

Volumn 97, Issue 11, 2007, Pages 1465-1468

  Schonthal A H ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

3 phosphoinositide dependent protein kinase 1; Carbonic anhydrases; Coxibs; Cyclooxygenase 2 independence; Endoplasmic reticulum (ER) stress

Indexed keywords

ACETAZOLAMIDE; ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; OSU 03012; PHOSPHATIDYLINOSITOL 3 KINASE; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CHRONIC PAIN; DRUG EFFECT; DRUG POTENCY; DRUG TARGETING; ENDOPLASMIC RETICULUM; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ANTINEOPLASTIC AGENTS; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SULFONAMIDES;

EID: 36448957271     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604049     Document Type: Short Survey

References (31)

1. Alloza I, Baxter A, Chen Q, Matthiesen R, Vandenbroeck K (2006) Celecoxib inhibits interleukin-12 alphabeta and beta2 folding and secretion by a novel COX2-independent mechanism involving chaperones of the endoplasmic reticulum. Mol Pharmacol 69: 1579-1587
2. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, Ogier-Denis E (2002) Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 277: 27613-27621
3. Di Fiore A, Pedone C, D'Ambrosio K, Scozzafava A, De Simone G, Supuran CT (2006) Carbonic anhydrase inhibitors: valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II 'selective' inhibitor celecoxib. Bioorg Med Chem Lett 16: 437-442
4. Fürstenberger G, Krieg P, Muller-Decker K, Habenicht AJ (2006) What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? Int J Cancer 119: 2247-2254
5. Grösch S, Maier TJ, Schiffmann S, Geisslinger G (2006) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98: 736-747
6. Grösch S, Tegeder I, Niederberger E, Bräutigam L, Geisslinger G (2001) COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15: 2742-2744
7. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275: 11397-11403
8. Johnson AJ, Hsu AL, Lin HP, Song X, Chen CS (2002) The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its antitumour effect and cardiovascular risks. Biochem J 366: 831-837
9. Kardosh A, Blumenthal M, Wang WJ, Chen TC, Schönthal AH (2004) Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol Ther 3: 9-16
10. Kardosh A, Wang W, Uddin J, Petasis NA, Hofman F, Chen CC, Schönthal AH (2005) Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the antitumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. Cancer Biol Ther 4: 571-582
11. Kashfi K, Rigas B (2005) Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol 70: 969-986
12. Kern MA, Schubert D, Sahi D, Schoneweiss MM, Moll I, Haugg AM, Dienes HP, Breuhahn K, Schirmacher P (2002) Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 36: 885-894
13. Kim SH, Hwang CI, Park WY, Lee JH, Song YS (2007) GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells. Carcinogenesis 28: 223-231
14. Knudsen JF, Carlsson U, Hammarstrom P, Sokol GH, Cantilena LR (2004) The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II. Inflammation 28: 285-290
15. Koehne CH, Dubois RN (2004) COX-2 inhibition and colorectal cancer. Semin Oncol 31: 12-21
16. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS (2004) 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 64: 1444-1451
17. Pastorekova S, Kopacek J, Pastorek J (2007) Carbonic anhydrase inhibitors and the management of cancer. Curr Top Med Chem 7: 865-878
18. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson Gd, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benze nesulfonamide (SC-58635, celecoxib). J Med Chem 40: 1347-1365
19. Potter CP, Harris AL (2003) Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 89: 2-7
20. Pyrko P, Kardosh A, Liu YT, Soriano N, Xiong W, Chow RH, Uddin J, Petasis NA, Mircheff AK, Farley RA, Louie SG, Chen TC, Schönthal AH (2007a) Calcium-activated ER stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib (DMC), a non-coxib analog of celecoxib. Mol Cancer Ther 6: 1262-1275
21. Pyrko P, Kardosh A, Schönthal AH (2007b) Celecoxib transiently inhibits protein synthesis. Biochem Pharmacol (in press)
22. Schönthal AH (2006) Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioblastoma therapy. Neurosurgical Focus 20, E21, 1-10
23. Schönthal AH (2007) Induction of apoptosis by celecoxib in cell culture: an uncertain role for COX-2. Cancer Research 67: 5575-5576
24. Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS (2002) Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 94: 585-591
25. Supuran CT, Scozzafava A, Casini A (2003) Carbonic anhydrase inhibitors. Med Res Rev 23: 146-189
26. Tanaka K, Tomisato W, Hoshino T, Ishihara T, Namba T, Aburaya M, Katsu T, Suzuki K, Tsutsumi S, Mizushima T (2005) Involvement of intracellular Ca2+ levels in nonsteroidal anti-inflammatory drug-induced apoptosis. J Biol Chem 280: 31059-31067
27. Tsutsumi S, Gotoh T, Tomisato W, Mima S, Hoshino T, Hwang HJ, Takenaka H, Tsuchiya T, Mori M, Mizushima T (2004) Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ 11: 1009-1016
28. Tsutsumi S, Namba T, Tanaka KI, Arai Y, Ishihara T, Aburaya M, Mima S, Hoshino T, Mizushima T (2006) Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells. Oncogene 25: 1018-1029
29. Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, Klebe G (2004) Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 47: 550-557
30. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN (2000) Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 60: 6045-6051
31. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK, Chen CS (2004) From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 64: 4309-4318